Autopsy report · NCT02487277

PEGPH20, Gemicitabine and Nab-Paclitaxel for Pancreatic Ductal Adenocarcinoma

“Low accrual”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 2 years 10 months before it stopped.
• 3 participants enrolled.
• Results were posted on the registry 1 year 7 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Andrew Ko

Sponsor type

University, hospital or other

Conditions

Adenocarcinoma

Interventions

PEGPH20; Gemcitabine; Nab-paclitaxel

Participants

3

Sites

1

Countries

United States

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.